Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 14, 2016 20:56:16 GMT -5
|
|
|
|
Post by patten1962 on Jun 14, 2016 21:07:41 GMT -5
|
|
|
|
Post by trondisc on Jun 15, 2016 3:25:10 GMT -5
Am I reading this wrong but these are completely irrelevant since the articles published have a timestamp of 2009 & 2012? Hope you aren't being misleading Mang0..."published June 14th, 2016"? GTFOH?
|
|
|
|
Post by mnholdem on Jun 15, 2016 6:35:38 GMT -5
Mango isn't misleading anyone. I've check several sources to confirm, as you should have done. The filing date may have been in 2009, but the publication date is June 14, 2016.
Example #1:
Application Number: 12/488469
Publication Date: 06/14/2016
Filing Date:06/19/2009
Source: www.freepatentsonline.com/9364619.html
---
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 15, 2016 7:02:54 GMT -5
|
|
|
|
Post by matt on Jun 15, 2016 7:33:07 GMT -5
The filing date, also called the priority date, is the date on which the patent application was lodged with the PTO. This is important for two reasons:
1. It is the date the authorities use to determine who was the first to discover an invention. First to file wins the patent. Under the old law if you could prove that you had discovered something earlier but you had filed later you could still be awarded the patent but that no longer happens, so filing date is of critical importance. The same priority date is carried over to foreign applications filed within the statutory.
2. If the patent is eventually granted, the 20 year life runs from the filing date (with some exceptions).
As part of the patent granting process, after the PTO has reviewed the application it has to be published so that other inventors can object to the scope of the claims or raise interference actions. That is where these patents are today; they have been published for objection but have not yet been granted.
Normally the time from application to publication is about 18-24 months, and publication to grant is another 12 months or so, but that time line varies widely. Some patent examiners are faster than others, some companies are faster in relying to questions and challenges than others, and the subject matter of the patent is important to the depth of the queue. In general, it is hard to say anything in general!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 15, 2016 7:34:37 GMT -5
If you don't have time to read everything from the first link, here is a few pieces parts. Technosphere should change the world of drug delivery but first things first. Affreza needs traction.
Delivery of drugs has been a major problem for many years, particularly when the compound to be delivered is unstable under the conditions encountered in the gastro-intestinal tract when administered orally to a subject, prior to reaching its targeted location. For example, it is preferable in many cases to administer drugs orally, especially in terms of ease of administration, patient compliance, and decreased cost. However, many compounds, including small organic molecules, peptides and proteins are ineffective or exhibit low or variable potency when administered orally. Presumably, this is because the drugs are unstable to conditions in the digestive tract or because they are inefficiently absorbed.
Due to the problems associated with oral drug delivery, drug delivery to the lungs has been explored. For example, typically, drugs delivered to the lungs are designed to have an effect on the tissue of the lungs, for example, vasodilators, surfactants, chemotherapeutic agents or vaccines for flu or other respiratory illnesses. Other drugs, including nucleotide drugs, have been delivered to the lungs because they represent a tissue particularly appropriate for treatment, for example, for genetic therapy in cystic fibrosis, where retroviral vectors expressing a defective adenosine deaminase are administered to the lungs in an attempt to correct the defective gene.
Drug delivery to the lungs for agents having systemic effects can also be performed. Advantages of the lungs for delivery of systemic agents include the large surface area and the ease of uptake by the lung's mucosal surface. One problem associated with all of these forms of pulmonary drug delivery is that it is difficult to deliver drugs into the lungs due to problems in getting the drugs past all of the natural barriers, such as the cilia lining the trachea, and in trying to administer a uniform volume and weight of drug. In addition, decreasing the amount of powder to be delivered to the lungs should be advantageous to the subject being treated so as to minimize coughing and prevent any loss of lung function, which can be a potential problem with increased amount of powders required to deliver an appropriate or increase in dose of an active agent. Accordingly, there is room for improvement in designing and providing pharmaceutical formulations requiring large amounts or doses of an active agent for pulmonary delivery to improve treatment and patience compliance.
In some embodiments, diketopiperazine microparticles comprise a drug or active agent, wherein said drug or active agent is a small organic molecule, peptide or protein. Examples of an endocrine hormone include, insulin, parathyroid hormone, calcitonin, glucagon, glucagon-like peptide 1, oxyntomodulin, oxytocin, CCK-8, PYY3-36, ghrelin and VIP (vasoactive intestinal peptide) an analog or active fragment of the endocrine hormone. Examples of small organic molecules include, a neurotransmitter agonist, a neurotransmitter antagonist, a pain inhibitory agent, including, morphine, and morphine derivatives, and triptans such as sumatriptan and rizatriptan, a vaccine, an anti-inflammatory agent, an anti-cancer agent, a cell receptor agonist molecule, or cell receptor antagonist molecule.
Glucon-Like Peptide aka: GLP1 does Sanofi retain rights to market this product delivered via Technosphere and for the scientists on this board, can Technosphere deliver other oral diabetes meds?
|
|
|
|
Post by slapshot on Jun 15, 2016 8:18:35 GMT -5
The filing date, also called the priority date, is the date on which the patent application was lodged with the PTO. This is important for two reasons: 1. It is the date the authorities use to determine who was the first to discover an invention. First to file wins the patent. Under the old law if you could prove that you had discovered something earlier but you had filed later you could still be awarded the patent but that no longer happens, so filing date is of critical importance. The same priority date is carried over to foreign applications filed within the statutory. 2. If the patent is eventually granted, the 20 year life runs from the filing date (with some exceptions). As part of the patent granting process, after the PTO has reviewed the application it has to be published so that other inventors can object to the scope of the claims or raise interference actions. That is where these patents are today; they have been published for objection but have not yet been granted. Normally the time from application to publication is about 18-24 months, and publication to grant is another 12 months or so, but that time line varies widely. Some patent examiners are faster than others, some companies are faster in relying to questions and challenges than others, and the subject matter of the patent is important to the depth of the queue. In general, it is hard to say anything in general! Matt is fairly accurate, but a few distinctions: First, these (9364619 & 9364436) are actually granted patents and were just issued 6/14/16. They were originally published as pre-grant publications (2009/0314292 & 2014/0199398). The patent terms will be 20 years from the effective (earliest) filing date, the priority date (based on a provisional) may be a year earlier but doesn't factor in to the term. Also, the terms can be extended (called PTA) if the patent office doesn't meet their deadlines during prosecution. '619 gets a 919 day PTA, and '436 gets a 107 day PTA (printed on front of patent)... however if applicable, the PTA cant extend the life beyond any terminal disclaimers filed during prosecution. I don't know if any terminal disclaimers were filed or not. The pre-grant publication is normally 18 months from the filing date, however will be from the provisional date (if applicable) for US filed applications and from the 371 date for applications based on PCTs (international applications). |
|
